VolitionRX (VNRX)

• Market cap: $53M
• 1 day: -4.13%
• 5 days: -3.07%
• 1 month: -12.30%
• 3 months: -31.87%
• 6 months: -18.75%
• Year to date: -12.30%
• 1 year: -43.05%
• 5 years: -87.91%
• 10 years: -86.36%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Employees: 110

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

27% more funds holding

Funds holding: 22 [Q3] → 28 (+6) [Q4]

6% more capital invested

Capital invested by funds: $10.5M [Q3] → $11.2M (+$680K) [Q4]

0.44% more ownership

Funds ownership: 19.03% [Q3] → 19.48% (+0.44%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 805% upside
• Avg. target: $5 805% upside
• High target: $5 805% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 36% 1-year accuracy 85 / 239 met price target

805% upside $5

Buy Maintained

6 Feb 2025